Patrick G. Pilié

3.7k total citations · 1 hit paper
43 papers, 1.8k citations indexed

About

Patrick G. Pilié is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Patrick G. Pilié has authored 43 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 19 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in Patrick G. Pilié's work include Prostate Cancer Treatment and Research (15 papers), PARP inhibition in cancer therapy (10 papers) and DNA Repair Mechanisms (8 papers). Patrick G. Pilié is often cited by papers focused on Prostate Cancer Treatment and Research (15 papers), PARP inhibition in cancer therapy (10 papers) and DNA Repair Mechanisms (8 papers). Patrick G. Pilié collaborates with scholars based in United States, United Kingdom and China. Patrick G. Pilié's co-authors include Timothy A. Yap, Gordon B. Mills, Chad Tang, Ross Stewart, Lauren A. Byers, Mark J. O’Connor, Carl M. Gay, Eric Jonasch, Daniel J. McGrail and Timothy C. Thompson and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Patrick G. Pilié

38 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

State-of-the-art strategies for targeting the DNA damage response in cancer

2018 795 citations Patrick G. Pilié, Chad Tang et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick G. Pilié United States	13	1.1k	1.1k	407	342	227	43	1.8k
Akihiko Shimomura Japan	22	751 0.7×	1.1k 1.0×	536 1.3×	537 1.6×	147 0.6×	132	2.0k
Lydia Gaba Spain	13	516 0.5×	786 0.7×	364 0.9×	487 1.4×	207 0.9×	47	1.4k
Rebeca Sanz‐Pamplona Spain	25	885 0.8×	669 0.6×	370 0.9×	496 1.5×	252 1.1×	67	1.8k
Leslie A. Parsels United States	24	1.5k 1.4×	1.4k 1.3×	289 0.7×	349 1.0×	155 0.7×	39	2.1k
Amir Sonnenblick Israel	22	743 0.7×	885 0.8×	212 0.5×	450 1.3×	234 1.0×	92	1.6k
L Rhoda Molife United Kingdom	18	836 0.8×	872 0.8×	419 1.0×	359 1.0×	115 0.5×	44	1.6k
Yanis Boumber United States	22	1.6k 1.5×	699 0.7×	420 1.0×	471 1.4×	192 0.8×	56	2.3k
Pradip De United States	22	1.0k 1.0×	988 0.9×	438 1.1×	596 1.7×	178 0.8×	36	2.0k
Yasir H. Ibrahim United States	12	1.1k 1.0×	828 0.8×	305 0.7×	249 0.7×	82 0.4×	22	1.6k
Alexander C. Klimowicz Canada	23	821 0.8×	653 0.6×	188 0.5×	280 0.8×	121 0.5×	56	1.5k

Countries citing papers authored by Patrick G. Pilié

Since Specialization

Citations

This map shows the geographic impact of Patrick G. Pilié's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick G. Pilié with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick G. Pilié more than expected).

Fields of papers citing papers by Patrick G. Pilié

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick G. Pilié. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick G. Pilié. The network helps show where Patrick G. Pilié may publish in the future.

Co-authorship network of co-authors of Patrick G. Pilié

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick G. Pilié. A scholar is included among the top collaborators of Patrick G. Pilié based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick G. Pilié. Patrick G. Pilié is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Singh, Pratishtha, Ranit D’Rozario, Deblina Raychaudhuri, et al.. (2026). Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer. Nature Communications. 17(1). 1382–1382.

Sherry, Alexander D., Cara Haymaker, Bryan Fellman, et al.. (2025). Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives.. Journal of Clinical Oncology. 43(5_suppl). 140–140. 1 indexed citations

Tidwell, Rebecca S., Yao Yu, Amado J. Zurita, et al.. (2024). Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocrine Related Cancer. 31(12).

Ngoi, Natalie Y.L., Patrick G. Pilié, Daniel J. McGrail, et al.. (2024). Targeting ATR in patients with cancer. Nature Reviews Clinical Oncology. 21(4). 278–293. 34 indexed citations

Liu, Xian-De, Yanting Zhang, Daniel J. McGrail, et al.. (2023). SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma. Clinical Cancer Research. 29(19). 4002–4015. 8 indexed citations

Manyam, Ganiraju C., Jody V. Vykoukal, Johannes F. Fahrmann, et al.. (2023). SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression. Clinical Cancer Research. 29(21). 4464–4478. 11 indexed citations

Tidwell, Rebecca S., Miao Zhang, Keyi Zhu, et al.. (2023). Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers. 15(24). 5843–5843. 2 indexed citations

Hahn, Andrew W., Rebecca S. Tidwell, Efstratios Koutroumpakis, et al.. (2023). A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio).. Journal of Clinical Oncology. 41(6_suppl). TPS273–TPS273. 1 indexed citations

Li, Xubin, Gonghong Yan, Jacob H. Elnaggar, et al.. (2022). Precision Combination Therapies Based on Recurrent Oncogenic Coalterations. Cancer Discovery. 12(6). 1542–1559. 20 indexed citations

10.

Tang, Zhe, Patrick G. Pilié, Chuandong Geng, et al.. (2021). ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer. Clinical Cancer Research. 27(17). 4898–4909. 97 indexed citations

11.

McGrail, Daniel J., Patrick G. Pilié, Hui Dai, et al.. (2021). Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Science Translational Medicine. 13(617). eabe6201–eabe6201. 22 indexed citations

12.

Garmezy, Benjamin, Patrick G. Pilié, Wenyi Wang, et al.. (2020). 77P Clinical characteristics and therapeutic implications of PALB2 variants in patients with advanced solid tumors. Annals of Oncology. 31. S270–S270. 1 indexed citations

13.

Pilié, Patrick G., Carl M. Gay, Lauren A. Byers, Mark J. O’Connor, & Timothy A. Yap. (2019). PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clinical Cancer Research. 25(13). 3759–3771. 244 indexed citations

14.

Pilié, Patrick G.. (2019). Genomic Instability in Kidney Cancer: Etiologies and Treatment Opportunities. 3(3). 143–150. 1 indexed citations

15.

Woodson, Ashley, Molly S. Daniels, Patrick G. Pilié, et al.. (2019). Real-world outcomes of genetic testing in a GU genetics clinic and evaluation of current guidelines.. Journal of Clinical Oncology. 37(7_suppl). 668–668. 1 indexed citations

16.

Jonasch, Eric, Ian E. McCutcheon, Dan S. Gombos, et al.. (2018). Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. The Lancet Oncology. 19(10). 1351–1359. 70 indexed citations

17.

Pilié, Patrick G., Chad Tang, Gordon B. Mills, & Timothy A. Yap. (2018). State-of-the-art strategies for targeting the DNA damage response in cancer. Nature Reviews Clinical Oncology. 16(2). 81–104. 795 indexed citations breakdown →

18.

Pilié, Patrick G. & Eric Jonasch. (2017). Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. PubMed. 1(1). 57–64. 10 indexed citations

19.

Pilié, Patrick G., Surena F. Matin, Ashley Woodson, et al.. (2016). Pilot study of dovitinib in patients with VHL disease.. Journal of Clinical Oncology. 34(2_suppl). 587–587. 1 indexed citations

20.

Petrilli, Christopher M., Patrick G. Pilié, Sanjay Saint, Daniel Kaul, & Andrew Odden. (2014). Bigger than his bite. Journal of Hospital Medicine. 10(1). 46–49. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact